Aims:

International conference to present, learn and discuss Pharmacometric Science and Applications. Official language is English.

Dates:

January 30(Wed) & 31(Thu), 2019

Program:

Day1, January 30th
13:30 Opening Remark Yusuke Tanigawara (Keio University School of Medicine)
13:40 Introduction of Tonomachi Wellbeing Research Ryota Yoshimoto (Center for Wellbeing Research, Keio University / Organizer, Research Complex Program)
13:55 Application of pharmacometrics for optimized drug development and personalized pharmacotherapy In-Jin Jang (Seoul National University and Hospital, South Korea)
14:25 PK/PD model informed drug clinical development in our practice Qingshan Zheng (Shanghai University of Chinese Medicine, China)
14:55 Simplification of multi-scale systems models for data-driven analyses Chihiro Hasegawa (Ono Pharmaceutical)
15:10 Population pharmacokinetic analysis of vancomycin in adult cancer patients Ken-ichi Sako (Nihon Pharmaceutical University)
15:25 Intermission
15:40 Challenges and Opportunities of Quantitative Pharmacology in Biologics Development Jin Yan Jin (ISoP President 2017-2018 (Genentech, U.S.A.) )
16:30 Overview of draft regulatory guideline on exposure-response analysis Yoshinori Ochiai (PMDA, Japan)
Day2, January 31st
9:30 Development of an open PBPK software (DAllPhin) for human PK prediction Dong-Seok Yim (The Catholic University of Korea, South Korea)
10:10 PopPKPD Analysis of Cisplatin Induced Nephrotoxicity: An Apoptotic Signal Transduction-Indirect Response Model Keizo Fukushima (Kobe Gakuin University)
10:25 Comparison of lifespan model and transit compartment model to model myelosuppression data Takanori Ogawa (Certara)
10:40 Preclinical PK/PD model -based human dose selection for anti-tumor drug OPC-X Tomohiro Sasaki (Otsuka Pharmaceutical)
10:55 Benefit-risk assessment of nivolumab flat dose relative to weight-based dosing regimen Mayu Osawa (Bristol-Myers Squibb)
11:10 Intermission
11:25 Tumor Growth Inhibition-Overall Survival Modeling and Simulation for Immunotherapies: A Case Study with Atezolizumab René Bruno (ISoP President 2016-2017 (Institut Roche, France))
12:15 Lunch
13:30 Pharmacokinetic and pharmacodynamic modelling of antimalarial drugs Joel Tarning (University of Oxford and Mahidol University, Thailand)
14:00 Pharmacokinetics and pharmacodynamics of vancomycin in patients with Enterococcal bacteremia Chen-Hsi Chou (National Cheng Kung University, Taiwan)
14:30 Population pharmacokinetics of teicoplanin in neonates and children Takaaki Yamada (Kyushu University Hospital)
14:45 Pharmacometric approach to optimize antibacterial regimens for drug-resistant infections Kazuro Ikawa (Hiroshima University)
15:00 A Markov Transition Model for Characterization of Exposure Response of Tofacitinib During Maintenance Therapy in Patients with Ulcerative Colitis Shinichi Tsuchiwata (Pfizer)
15:15 Intermission
15:25 Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid Hidefumi Kasai (Keio University)
15:50 Pharmacometrics time-to-event modelling of recurrent stroke among patients with type 2 diabetes mellitus Siti Maisharah Sheikh Ghadzi (Universiti Sains Malaysia, Malaysia)
16:15 Current status of research and education of pharmacometrics in Malaysia Lo Yoke Lin (International Medical University in Kuala Lumpur, Malaysia)
16:35 Closing remark Yusuke Tanigawara (Keio University School of Medicine)

Venue:

Keio University Mita Campus, North Building Conference Hall.
Address: 2-15-45 Mita, Minato-ku, Tokyo 108-8345, Japan.
https://www.keio.ac.jp/en/maps/mita.html

Registration:

Admission fee is free, but advanced registration is required.

Registration Deadline :

January 25(Fri), 2019

Organizer:

Keio University, in support of Japan Science and Technology Agency (JST), and with auspices of International Society of Pharmacometrics (ISoP) and Japan Pharmaceutical Manufacturers Association (JPMA).

Chair:

Professor Yusuke Tanigawara,Ph.D.

Keio University School of Medicine
Department of Clinical Pharmacokinetics and Pharmacodynamics

State-of-the-Art Lectures:

René Bruno

ISoP President 2016-2017 (Institut Roche, France)

‘Tumor Growth Inhibition-Overall Survival Modeling and Simulation for Immunotherapies: A Case Study with Atezolizumab.’

Jin Yan Jin

ISoP President 2017-2018 (Genentech, U.S.A.)

‘Challenges and Opportunities of Quantitative Pharmacology in Biologics Development.’

Invited Lectures:

Yoshinori Ochiai

PMDA, Japan

‘Overview of draft regulatory guideline on exposure-response analysis’

Qingshan Zheng

Shanghai University of Chinese Medicine, China

‘PK/PD model informed drug clinical development in our practice’

Dong-Seok Yim

The Catholic University of Korea, South Korea

‘Development of an open PBPK software (DAllPhin) for human PK prediction’

In-Jin Jang

Seoul National University and Hospital, South Korea

‘Application of pharmacometrics for optimized drug development and personalized pharmacotherapy’

Chen-Hsi Chou

National Cheng Kung University, Taiwan

‘Pharmacokinetics and pharmacodynamics of vancomycin in patients with Enterococcal bacteremia’

Joel Tarning

University of Oxford and Mahidol University, Thailand

‘Pharmacokinetic and pharmacodynamic modelling of antimalarial drugs’

Lo YokeLin

International Medical University in Kuala Lumpur, Malaysia

‘Current status of research and education of pharmacometrics in Malaysia’

Siti Maisharah Sheikh Ghadzi

Universiti Sains Malaysia, Malaysia

‘Pharmacometrics time-to-event modelling of recurrent stroke among patients with type 2 diabetes mellitus’

Oral presentations by the Course students:

Mayu Osawa (Bristol-Myers Squibb)
‘Benefit-risk assessment of nivolumab flat dose relative to weight-based dosing regimen’

Keizo Fukushima (Kobe Gauin University)
‘PopPKPD analysis of cisplatin induced nephrotoxicity: an apoptotic signal transduction-indirect response model’

Takaaki Yamada (Kyushu University Hospital)
‘Population pharmacokinetics of teicoplanin in neonates and children’

Shinichi Tsuchiwata (Pfizer)
‘A Markov transition model for characterization of exposure–response of tofacitinib during maintenance therapy in patients with ulcerative colitis’

Tomohiro Sasaki (Otsuka Pharmaceutical)
‘Preclinical PK/PD model-based human dose selection for anti-tumor drug OPC-X’

Chihiro Hasegawa (Ono Pharmaceutical)
‘Simplification of multi-scale systems models for data-driven analyses’

Oral presentations by the Course tutors:

Hidefumi Kasai (Keio University)
‘Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid’

Takanori Ogawa (Certara)
‘Comparison of life span model and transit compartment model to model real clinical data’

Kazuro Ikawa (Hiroshima University)
‘Pharmacometric approach to optimize antibacterial regimens for drug-resistant infections’

Ken-ichi Sako (Nihon Pharmaceutical University)
‘Population pharmacokinetic analysis of vancomycin in adult cancer patients’